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Abstract
Linezolid, which targets the ribosome, is a new synthetic antibiotic that is used for treatment of
infections caused by Gram-positive pathogens. Clinical resistance to linezolid, so far, has been
developing only slowly and has involved exclusively target site mutations. We have discovered that
linezolid resistance in a methicillin-resistant Staphylococcus aureus hospital strain from Colombia
is determined by the presence of the cfr gene whose product, Cfr methyltransferase, modifies
adenosine at position 2503 in 23S rRNA in the large ribosomal subunit. The molecular model of the
linezolid-ribosome complex reveals localization of A2503 within the drug-binding site. The natural
function of cfr likely involves protection against natural antibiotics whose site of action overlaps that
of linezolid. In the chromosome of the clinical strain, cfr is linked to ermB, a gene responsible for
dimethylation of A2058 in 23S rRNA. Co-expression of these two genes confers resistance to all the
clinically-relevant antibiotics that target the large ribosomal subunit. The association of the ermB/
cfr operon with transposon and plasmid genetic elements indicate its possible mobile nature. This is
the first example of clinical resistance to the synthetic drug linezolid which involves a natural
resistance gene with the capability of disseminating among Gram-positive pathogenic strains.
INTRODUCTION
An oxazolidinone drug linezolid is one of the newest clinically-important antibiotics. Approved
for clinical use in 2000, it represented the first new class of antibiotics introduced into medical
practice in more than a quarter of a century (Hutchinson, 2003). Linezolid is a synthetic
inhibitor of protein synthesis that is active against many Gram-positive bacteria, including such
pathogens as methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant
enterococci and penicillin-resistant pneumococci. It is often used for treatment of complicated
infections when other therapies have failed (Bozdogan and Appelbaum, 2004).
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Linezolid inhibits protein synthesis by binding to the large ribosomal subunit (Lin et al.,
1997). Mutational and crosslinking studies revealed that the ribosomal peptidyl transferase
center is the target of drug action (Kloss et al., 1999; Xiong et al., 2000; Prystowsky et al.,
2001; Meka et al., 2004; Colca et al., 2003; Sander et al., 2002). The drug binding site is
composed of rRNA residues that form the inner shell of the peptidyl transferase active site
(Colca et al., 2003; Skripkin et al., 2005; Leach et al., 2007). Although the binding site of
linezolid overlaps with those of several other peptidyl transferase inhibitors, its interactions
with the ribosome are specific enough to allow for linezolid activity against bacterial pathogens
that developed resistance to other antibiotics that target the ribosome (Shinabarger, 1999).
One of the critical advantages of linezolid over currently used antibiotics is its entirely synthetic
nature. All other inhibitors of protein synthesis are derived from natural antibiotics of microbial
origin whose producers serve as the natural reservoirs of resistance genes (Cundliffe, 1989;
Poehlsgaard and Douthwaite, 2005). Acquisition of these genes through horizontal gene
transfer is one of the most common ways through which clinical pathogens develop antibiotic
resistance (Franceschi et al., 2004; Weisblum, 1995). Often associated with mobile genetic
elements, natural resistance genes can rapidly spread among pathogenic strains and impede
the clinical value of many important drugs (Bozdogan et al., 2004; Reyes et al., 2007; Roberts
et al., 1999; Robicsek et al., 2006). Since linezolid is a synthetic compound which does not
have natural prototypes it was expected that there is no natural pool of resistance genes which
could facilitate the development of clinical resistance. Indeed, the only mechanism of resistance
to linezolid in clinical isolates reported to date is due to mutations in the drug target site,
primarily the rRNA of the large ribosomal subunit (Meka and Gold, 2004; Prystowsky et al.,
2001). This type of resistance appears rarely, develops slowly because of the redundancy of
rRNA genes in bacteria, and is not transferable between pathogenic species. In all the reported
cases, the resistance was apparently generated de novo through spontaneous mutations rather
than via genetic exchange.
We report here the first example of a linezolid resistance mechanism in a clinical MRSA strain
that is based on acquisition of a natural and potentially transferable resistance gene. The product
of this gene modifies a specific rRNA nucleotide located in the site of the drug action. In the
chromosome of the clinical MRSA strain, this gene is apparently associated with mobile genetic
elements which raises the possibility of its transmission to other pathogenic strains.
RESULTS
The linezolid-resistant MRSA isolate lacks known resistance mutations
A MRSA strain CM05 isolated in 2005 in Medellin, Colombia from a patient with a fatal
ventilator-associated pneumonia exhibited resistance to linezolid (16 µg/ml) as well as to
several other antibiotics (Table 1). This patient received only two doses of linezolid, and thus,
the emergence of linezolid resistance was rather unexpected since this phenomenon has been
previously associated with prolonged treatment with the antibiotic. This prompted us to
investigate the mechanism of linezolid resistance in the CM05 MRSA strain. All known cases
of linezolid resistance in clinical isolates of Gram-positive pathogens have been associated
with mutations in the drug target site: domain V of 23S ribosomal RNA or protein L4 (Meka
and Gold, 2004;Wolter et al., 2005). Nonetheless, sequencing of the PCR-amplified domain
V of 23S rRNA of the CM05 isolate did not reveal any mutation (the sensitivity of the assay
was sufficient to detect the presence of a mutation even in a single out of five or six rrn alleles
present in staphylococci (Wada et al., 1993)). Similarly, no mutation was found in the L4
protein gene PCR-amplified from genomic DNA of the CM05 isolate. The lack of target site
mutations in the linezolid-resistant MRSA strain indicated that a new molecular mechanism
was responsible for resistance of the isolate to linezolid.
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An unusual posttranscriptional modification at position 2503 causes linezolid resistance in
the MRSA CM05
Resistance to ribosome-targeting antibiotics is often conferred by modification of specific
nucleotide residues in rRNA (Kehrenberg et al., 2005; Mann et al., 2001; Treede et al.,
2003; Weisblum, 1995). When rRNA from the CM05 isolate was examined by primer
extension, we noticed a reverse transcriptase stop at A2058 in 23S rRNA (Figure 1A).
Subsequent analysis showed that this effect is explained by the presence of ermB
methyltransferase gene in the MRSA CM05 strain. The ErmB methyltransferase dimethylates
A2058 conferring resistance to macrolides, lincosamides and streptogramins B (MLSB
resistance) and may account, at least in part, for the observed resistance of the CM05 isolate
to erythromycin and clindamycin (Table 1). The second strong reverse transcriptase stop
indicated that another 23S rRNA nucleotide, A2503, carries an unusual posttranscriptional
modification (Figure 1B). A2503 is a component of the linezolid binding site (Leach et al.,
2007) and it is conceivable that modification of this rRNA residue may affect binding or action
of the drug. A recent report by Kehrenberg et al. (2005) indicated that in staphylococci isolates
from animals, A2503 can be a subject of posttranscriptional modification by a
methyltransferase Cfr. The initial reports suggested that this modification could confer
resistance to the peptidyl transferase targeting antibiotics florfenicol, chloramphenicol and
clindamycin (Kehrenberg et al., 2005; Schwarz et al., 2000). Even though the cfr gene was
never before found in clinical isolates, the finding of Kehrenberg et al. prompted us to test the
presence of this gene in the clinical MRSA strain. PCR analysis carried out with cfr-specific
primers indicated the presence of the cfr gene in the CM05 genome and thus revealed it as a
putative cause of linezolid resistance of the clinical MRSA (Figure 1C).
In order to investigate whether the presence of cfr and the resulting modification of A2503 was
indeed the cause of linezolid resistance of the CM05 isolate, the complete cfr ORF was PCR
amplified, sequenced and cloned into the pLI50 vector under the control of Pspac promoter
(Lee et al., 1991; Yansura and Henner, 1984). The 1050-nt long sequence of the cfr gene in
the CM05 MRSA isolate was identical to that of cfr in the plasmid pSCFS1 reported by Schwarz
and co-workers (Kehrenberg et al., 2004). Introduction of the resulting plasmid, pLXM1, into
S. aureus RN4220 cells led to a 4-fold increase in MIC to linezolid (Table 1). Linezolid
resistance of the transformants correlated with the appearance of the characteristic reverse
transcriptase stop corresponding to the unusual modification of A2503 (Figure 1B). This result
established a causative relationship between the presence of the cfr gene in the MRSA clinical
strain, posttranscriptional modification of A2503, and linezolid resistance.
Location of cfr in the MRSA CM05 genome
The cfr gene was previously found only in staphylococcal isolates from animal sources and
almost exclusively on plasmids that ranged in size from 17 to 43 kb (Kehrenberg et al.,
2004; Kehrenberg and Schwarz, 2006; Kehrenberg et al., 2007). Even though the CM05 MRSA
carries a 32 kb plasmid (Figure 2A), Southern blotting analysis showed that in the CM05
genome, cfr is located on the chromosome (Figure 2 B and C). In agreement with this finding,
the plasmid from the CM05 isolate failed to render recipient S. aureus cells resistant to linezolid
(not shown).
Sequencing of the cloned cfr-containing 5.8 kb HindIII/EcoRI chromosomal DNA fragment
revealed that cfr was located downstream of the ermB gene which encodes a rRNA
methyltransferase that dimethylates A2058 in the 23S rRNA and confers resistance to
macrolides, lincosamides and streptogramins B (MLSB resistance) (Shaw and Clewell, 1985)
(Figure 3). The ermB/cfr cluster is flanked on one side by the transposase/cointegrase gene
istAS from the IS21-558 mobile genetic element. PCR analysis showed the presence of the
complete IS21-558 (Smith and Mankin, unpublished). The IS21-558 element was shown to be
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implicated in the mobility of the cfr gene in animal isolates (Kehrenberg et al., 2007) and might
contribute to its mobilization in the clinical strain.
Upstream from ermB, a 5’ segment of the gene repS is present. Its product, the RepS protein,
is involved in initiation of plasmid replication (Hashiba et al., 1993). A close association of
the cfr gene with a characteristic plasmid gene indicates that integration of a plasmid carrying
the cfr gene in the chromosome of CM05 cells, was the likely route of acquisition of linezolid
resistance by the MRSA human isolate.
DISCUSSION
We presented evidence that resistance of a clinical MRSA strain CM05 to a synthetic antibiotic
linezolid is caused, at least in part, by acquisition of a gene whose product is responsible for a
specific posttranscriptional modification of a 23S rRNA nucleotide located in the site of drug
action.
A causative relationship between the presence of cfr and resistance of the clinical MRSA strain
to linezolid is demonstrated by the fact that introduction of cfr into a linezolid-sensitive S.
aureus strain notably increased its resistance to the drug and led to the appearance of an unusual
posttranscriptional modification at A2503 in 23S rRNA but not at A2058. (Table 1 and Figure
1B). A similar effect was recently demonstrated by Long et al. (Long et al., 2006) who used a
different construct to show that a cfr-containing DNA segment from animal isolates of
staphylococci rendered recipient cells resistant to several peptidyl transferase-targeting
antibiotics, including oxazolidinones. Since cfr-based resistance affects specifically the large
ribosomal subunit, it is obvious that other determinants are present in the clinical MRSA CM05
strain that render it resistant to antibiotics affecting different targets (Table 1).
The exact nature of posttranscriptional modification introduced by the Cfr enzyme is unknown.
In wild type E. coli, A2503 is mono-methylated at the adenine ring and is present in the
ribosome in the form of m2A (Kowalak et al., 1995). Though the status of A2503 in wild type
S. aureus is unknown, the presence of a weak reverse transcriptase stop at this position (Figure
1) suggests that, similar to E. coli, it might also carry a posttranscriptional modification. Closely
homologous genes of methyltransferase enzymes, which are likely responsible for the ‘wild
type modification’ of A2503, are present in the E. coli and S. aureus genomes (Toh and Mankin,
in preparation). Expressed in E. coli, Cfr was shown to add an extra methyl group to m2A2503
(Kehrenberg et al., 2005). However, the exact location of the extra methyl group added by Cfr
remained ambiguous. By extrapolation, we expect that S. aureus cells carrying the cfr gene
also end up having two methyl groups at A2503.
The molecular model of linezolid bound to the bacterial ribosome shows close proximity of
the C5 side chain of the drug to A2503 (Leach et al., 2007) (Figure 4). A methyl group at 2’
oxygen of the A2503 ribose or C8 carbon of the A2503 base will come into close proximity
to the C5 side chain of linezolid and could affect its placement in the ribosome. Alternatively,
an additional methyl group at the adenine base can change its conformation from syn, as
modeled in the E. coli wild type ribosome, to anti which would result in the direct clash of the
nitrogen base with the antibiotic (Schuwirth et al., 2005; Selmer et al., 2006). Since A2503 is
also involved in binding of other peptidyl transferase targeting antibiotics, it is not surprising
that its modification by the Cfr enzyme renders cells resistant to a large array of peptidyl
transferase inhibitors (Hansen et al., 2003; Kehrenberg et al., 2005; Long et al., 2006;
Schlunzen et al., 2001).
The genetic organization of the cfr gene in the chromosome of the strain CM05 is remarkable.
The putative cfr promoter sequence identified in the pSCFS1, pSCFS3 and pSCFS6 plasmids
in staphylococci from animal sources (Kehrenberg and Schwarz, 2006) has been eliminated in
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MRSA CM05 due to the insertion of the ermB gene (The latter was likely delivered by the
tn917 transposon as indicated by the presence of the tn917 inverted repeats surrounding the
ermB gene). No other obvious promoter sequence is found in the intergenic spacer between
ermB and cfr. RT-PCR analysis showed the presence of transcripts that span both ermB and
cfr genes indicating that cfr is likely co-transcribed with ermB (Smith and Mankin,
unpublished). Both Cfr and ErmB are rRNA methyltransferases. ErmB dimethylates N6 of
A2058 in 23S rRNA conferring the MLSB type of resistance. Methylation of A2503 by Cfr
renders cells resistant to oxazolidinones, phenicols, lincosamides, streptogramins A and
pleuromutilins (Long et al., 2006). Thus, expression of ermB and cfr as a part of one operon
(which we designate mlr for modification of large ribosomal subunit) should result in
modification of two 23S rRNA nucleotides, A2058 and A2503, and render cells resistant to
all the clinical antibiotics acting upon the large ribosomal subunits. To our knowledge, the
mlr operon represents the first example of a single transcription unit affording resistance to
such a diverse spectrum of ribosomal antibiotics. Simultaneous modification of two rRNA
nucleotides within a drug binding site may synergistically increase antibiotic resistance (Treede
et al., 2003; Liu and Douthwaite, 2002). While A2058 is not a part of the linezolid binding site
in the ribosome and thus its modification is not expected to contribute to linezolid resistance,
simultaneous modification of A2503 by Cfr and of A2058 by ErmB may have a strong effect
on cell susceptibility to streptogramins because in their ribosome-bound form, two
streptogramin components, A and B, are in a close contact with A2503 and A2058, respectively
(Harms et al., 2004; Tu et al., 2005; Long et al., 2006). Testing the effects of A2503 and A2058
methylation on susceptibility to streptogramins is currently in progress (Smith and Mankin,
unpublished).
The putative mobile nature of the mlr operon is worrisome, since it can compromise treatment
of various Gram-positive infections in humans. Previously, the cfr gene was found primarily
on plasmids which could be easily exchanged between staphylococcal strains in animals
(Kehrenberg and Schwarz, 2006; Kehrenberg et al., 2007). In the clinical MRSA strain, the
cfr gene is present on the chromosome but is positioned next to the repS gene whose product
is involved in the control of plasmid copy number (Hashiba et al., 1993). This proximity
indicates that in the CM05 chromosome cfr resides on an integrated plasmid which could retain
its ability for excision and transmission. The repS gene in the CM05 chromosome shows high
homology to repS from streptococcal and enterococcal plasmids (Ceglowski and Alonso,
1994; Paulsen et al., 2003). This opens the general possibility of transmission of the mlr operon
to a variety of pathogenic strains. Interestingly, the ermB gene, which in the MRSA CM05
strain is found next to cfr, is prevalent in enterococcal strains while only ermA has been found
so far in Colombian MRSA isolates (Reyes et al., 2007). This finding may indicate that mlr
operon was actually formed in an enterococcal strain and subsequently was brought on a
plasmid into the genome of MRSA CM05. Pulse-field gel electrophoresis analysis of DNA of
the CM05 strain revealed its close relation to the so called Chilean MRSA clone that emerged
within the last five years and is currently accounting for the majority of hospital S. aureus
infections in Colombia (Arias et al., 2006). Neither of the other tested Colombian S. aureus
clones, including those which show a DNA fragmentation pattern similar to CM05, showed
resistance to linezolid and thus are unlikely to carry cfr (Arias et al., 2006). Thus, it appears
that acquisition of cfr by the Chilean clone is a recent event. In CM05 chromosome, the mlr
operon is adjacent to the IS21-558 mobile genetic element which was previously shown to be
implicated in cfr transposition in pSCFS3 and pSCFS6 plasmids in animal isolates (Kehrenberg
and Schwarz, 2006; Kehrenberg et al., 2007). This proximity opens another route – through
genetic transposition – for dissemination of the mlr operon to other pathogenic strains.
One of the perceived advantages of linezolid was its entirely synthetic nature which was
expected to help evade natural resistance mechanisms. However, since linezolid binds to the
same ribosomal site that is used by several classes of peptidyl transferase inhibitors (Leach et
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al., 2007; Moazed and Noller, 1987; Porse and Garrett, 1999; Poulsen et al., 2001), it is feasible
that a natural resistance mechanism that targets the peptidyl transferase center renders cells
resistant to this synthetic antibiotic. Even though the origin of cfr is unknown, the gene has
likely originated in a microbial producer of one of the natural peptidyl transferase inhibitors.
The acquisition, maintenance and spread of cfr among staphylococci that infect farm animals
could be promoted by the use of phenicols and lincosamides in veterinary practice as well as
the use of these antibiotics as growth promoters (Aarestrup et al., 2000; Schwarz et al.,
2004). Our data re-emphasize the fact that a reservoir of resistance genes in the animal industry
could potentially jeopardize the usefulness of clinical antibiotics, even those that do not have
natural prototypes.
EXPERIMENTAL PROCEDURES
The linezolid-resistant clinical isolate of S. aureus and its microbiological testing
Linezolid- and methicillin-resistant S. aureus was isolated in 2005 in Medellin, Colombia from
the sputum of a patient with a fatal ventilator-associated pneumonia. The isolate was designated
CM05. The patient had received only two doses of linezolid, 600 mg each, one day prior to
isolation of the culture. Typing of the isolate as methicillin-resistant S. aureus was based on
the BactiStaph latex agglutination assay (Remel, Lenexa, KS) and growth on Mueller-Hinton
plates containing 6 µg/ml oxacillin, in accordance with CLSI guidelines (Standards, 2003).
Antibiotic sensitivity testing was done using a CLSI-approved broth microdilution protocol or
E-test (for clindamycin). S. aureus strain ATCC 29213 was included as control.
Isolation of genomic DNA, plasmid DNA and total cellular RNA
Genomic DNA was isolated from S. aureus strains using a cetyltrimethylammonium bromide
(CTAB) method (Ausebel et al., 1987). The only difference with the published protocol was
the addition of lysostaphin to 40 µg/ml and incubation for 30 min at 37°C prior to addition of
RNase.
Plasmid DNA was extracted from the CM05 strain following the maxi-prep alkaline lysis
procedure (Sambrook et al., 1989) with the addition of a lysostaphin treatment step.
Supercoiled circular DNA was further purified by CsCl centrifugation. The size of the plasmid
was calculated as the sum of the fragment sizes obtained after digestion of the plasmid with
restriction enzymes.
For isolation of total RNA, S. aureus cells (the clinical isolate CM05 or wild type RN6390B
strain (Balaban and Novick, 1995) were grown in tryptic soy broth to an optical density of
A550 = 1.0. RNA was isolated using the UltraClean Microbial RNA Isolation Kit (Mo Bio
Laboratories, Carlsbad, CA) according to the manufacturer’s protocol.
Testing for the presence of known linezolid resistance mutations
Domain V of 23S rRNA gene was PCR amplified from total DNA of the CM05 isolate and a
linezolid-sensitive control, S. aureus strain (ATCC 29213) using primers,
GTGAAATCATAGTACCTGTGAAG and TTGATTAAGTCTTCGATCGATTAG,
corresponding to positions 2010–2032 and 2880–2904 of 23S rRNA. The resulting 887 bp
DNA fragment was sequenced using the same primers. In addition, the PCR fragment was
treated with restriction enzyme NheI and analyzed by agarose gel electrophoresis to confirm
the absence of the most common linezolid resistance mutation (G2576T) which generates a
new NheI site. The gene of ribosomal protein L4 was PCR-amplified from DNA of the CM05
isolate using primers CAGTGATTACGGGGCGCTTAAG and
GTAATAAATAATAAGAAGTGAAAGG and sequenced.
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Primer-extension analysis of rRNA
5 pmol of one of the 5’[32P]-labeled primers, GTCCATCCCGGTCCTCTCGTAC,
GCCGACATCGAGGTGCC or TAGTATCCCACCAGCGTCTC, was annealed to 2 µg of
total S. aureus RNA and extended using AMV reverse transcriptase (Seikagaku America) using
the described protocol (Merryman and Noller, 1998). The cDNA products of the primer
extension reactions were separated on 6% polyacrylamide sequencing gels.
Modeling the interaction of linezolid with A2503 in the ribosome
The modeling of linezolid placement in its ribosomal binding site based on the in vivo
crosslinking data and crystallographic structure of the E. coli ribosome will be described
elsewhere (Leach et al., 2007). In order to generate Figure 4, the C2-methyl group was added
to the adenine 2503 base computationally.
Detection, cloning and sequencing of the cfr gene
The presence of the cfr gene in the CM05 isolate (Schwarz et al., 2000) was verified by PCR
using a pair of primers ATGAATTTTAATAATAAAACAAAG and
TACACCCAAAATTACATCCG. The complete cfr gene was PCR amplified using the
primers ATGAATTTTAATAATAAAACAAAG and
CTATTGGCTATTTTGATAATTACC and cloned into the shuttle vector pLI50 (Lee et al.,
1991) under the control of a B. subtilis promoter Pspac (Yansura and Henner, 1984) to produce
plasmid pLXM1. In order to investigate the physical arrangement of cfr on the chromosome
of the CM05 strain, a 5.8 kb EcoRI/ HindIII fragment of CM05 genomic DNA, containing the
cfr gene, was cloned into the corresponding sites of the pBR322 vector to produce plasmid
pMS1. The cloned segment was sequenced by primer walking.
A 4.9 kb HindIII-XbaI fragment of the CM05 DNA insert was excised from pMS1 and cloned
into the corresponding sites of pLI50. The resulting plasmid, pMS2, as well as pLXM1 and
the empty pLI50 vectors were introduced in S. aureus RN4220 cells by electroporation (Schenk
and Laddaga, 1992). The transformants were selected on tryptic soy agar plates supplemented
with 10 µg/ml of chloramphenicol.
For Southern blotting analysis, total DNA or purified plasmid DNA from S. aureus CM05 was
digested with restriction enzymes EcoR1, HindIII, PstI or their combinations. DNA was
fractionated in a 0.8% agarose gel, transferred to Hybond-N+ membranes (Amersham
Biosciences) and hybridized with the PCR-amplified and radiolabeled full-length cfr gene.
Nucleotide sequence accession numbers
The sequence of a 5,822-bp segment of S. aureus CM/05 including the ermB and cfr region
and its flanking areas has been deposited to the NCBI database under accession number
EF450709.
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Figure 1.
An unusual posttranscriptional modification of A2503 in 23S rRNA of the clinical MRSA
isolate. Primer extension analysis of 23S rRNA isolated from a control wild type strain
RN6390B (wt) and clinical linezolid-resistant S. aureus strain CM05 (CM05) or a laboratory
strain RN4220 transformed with an empty vector pLI50 (vector) or cfr-expressing plasmid
pLXM1 (pLXM1). Sequencing lanes are marked (G, A). The position of the reverse
transcriptase stop corresponding to characteristic posttranscriptional modifications at A2058
and A2503 are indicated by arrows. A, ErmB-specific dimethylation of A2058. B and C, Cfr-
specific modification of A2503. D. PCR amplification of a 330 bp portion of the cfr gene from
the genome of CM05 cells. Similar amount of template DNA prepared from wild type S.
aureus cells was used in the control (wt).
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Figure 2.
Localization of the cfr gene on the chromosome of the S. aureus CM05 strain. A), Restriction
analysis of the 32-kb plasmid isolated from the CM05 strain. B), C), Southern blotting analysis
of the total genomic (G) or plasmid (P) DNA prepared from the CM05 cells. The full-length
cfr probe was used for hybridization. The sizes of DNA fragments in the DNA marker are
indicated.
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Figure 3.
The gene cfr and its environment on the chromosome of the S. aureus strain CM05. The
complete genes present within the sequenced regions are shown as solid arrows and incomplete
genes are shown as solid rectangles. The unsequenced parts of the identified genes are shown
as contoured arrows. The presence of the presumably complete istAS and istBS genes
constituting the IS21–558 insertion sequence was verified by PCR (Smith and Mankin,
unpublished). The location of the ermB and cfr leader ORFs (ermBL and cfrL, respectively)
which might be involved in translation attenuation is shown. The ermB promoter (Perm)
upstream of the ermB gene and a putative terminator (term) downstream from the cfr gene
which might control transcription of the mlr operon are shown. The 290 bp-long inverted
repeats flanking the ermB gene, which include the 28 bp-long transposon tn917 repeats, are
shown by arrows. The scale is in bp.
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Figure 4.
The proximity of A2503, which is the target of Cfr-modification, to linezolid bound in the A-
site of the bacterial ribosome. The orientation and placement of linezolid within its binding
site in the translating bacterial ribosome was taken from the reference (Leach et al., 2007).
RNA nucleotides constituting the linezolid binding site are shown as lines (blue) and are also
rendered as a surface representation. Linezolid and A2503 are shown as sticks. A 2-methyl
group has been computationally added to A2503. In linezolid, carbon atoms are colored orange,
nitrogens - blue, oxygens - red and fluorine is light-blue. The proximity of 2’O and C8 of
A2503 with the linezolid C5 side chain is indicated by dashed lines.
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